{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:12:52Z","timestamp":1781835172115,"version":"3.54.5"},"reference-count":19,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007816","name":"Alcon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007816","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acta Ophthalmologica"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To compare the additive effects and safety of 1% brinzolamide\/0.5% timolol fixed combination (<jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content>) versus the low\u2010dose regimen of 1% dorzolamide\/0.5% timolol fixed combination (<jats:styled-content style=\"fixed-case\">DTFC<\/jats:styled-content>) in patients with open\u2010angle glaucoma and ocular hypertension (<jats:styled-content style=\"fixed-case\">OAG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">OH<\/jats:styled-content>) following treatment with prostaglandin analogues (<jats:styled-content style=\"fixed-case\">PGA<\/jats:styled-content>s).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A prospective, randomized, double\u2010masked, multicentre, parallel\u2010group and active\u2010controlled study included 201 Japanese <jats:styled-content style=\"fixed-case\">OAG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">OH<\/jats:styled-content> patients who\u00a0had been treated with <jats:styled-content style=\"fixed-case\">PGA<\/jats:styled-content>. Efficacy was assessed as the change in intra\u2010ocular pressure (<jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content>) from baseline after weeks 4 and 8. Safety was assessed with adverse event rates, ocular discomfort score, blur scale, blood\u00a0pressure and heart rates, best\u2010corrected visual acuity (BCVA) and slit lamp examinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Intra\u2010ocular pressure (IOP) change from baseline at 9\u00a0<jats:styled-content style=\"fixed-case\">AM<\/jats:styled-content>\/11\u00a0<jats:styled-content style=\"fixed-case\">AM<\/jats:styled-content> pooled over the 8\u00a0weeks was \u22123.3\/\u22123.3\u00a0mmHg in the <jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content> group and \u22122.9\/\u22123.4\u00a0mmHg in the <jats:styled-content style=\"fixed-case\">DTFC<\/jats:styled-content> group, demonstrating non\u2010inferiority of <jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content> to <jats:styled-content style=\"fixed-case\">DTFC<\/jats:styled-content>. Ocular irritation was frequently seen in <jats:styled-content style=\"fixed-case\">DTFC<\/jats:styled-content> group. Although blurred vision was frequently seen in <jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content> group, it was transient and blurring became the equivalent 3\u00a0min after instillation between two groups. No noteworthy issue was observed in other safety outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Non\u2010inferiority of <jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content> to <jats:styled-content style=\"fixed-case\">DTFC<\/jats:styled-content> in <jats:styled-content style=\"fixed-case\">IOP<\/jats:styled-content> reduction was demonstrated after adding onto <jats:styled-content style=\"fixed-case\">PGA<\/jats:styled-content> therapy in Japanese <jats:styled-content style=\"fixed-case\">OAG<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">OH<\/jats:styled-content> patients. Although the score of blurred vision was transiently higher in <jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content> than <jats:styled-content style=\"fixed-case\">DTFC<\/jats:styled-content>, treatment difference decreased and disappeared with time. Thus,\u00a0<jats:styled-content style=\"fixed-case\">BTFC<\/jats:styled-content> can be considered as a safe and effective agent for glaucoma treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/aos.13401","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T07:05:38Z","timestamp":1491375938000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Additive effects and safety of fixed combination therapy with 1% brinzolamide and 0.5% timolol versus 1% dorzolamide and 0.5% timolol in prostaglandin\u2010treated glaucoma patients"],"prefix":"10.1111","volume":"95","author":[{"given":"Makoto","family":"Aihara","sequence":"first","affiliation":[{"name":"Department of Ophthalmology University of Tokyo Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misato","family":"Adachi","sequence":"additional","affiliation":[{"name":"Eye Rose Clinic Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Matsuo Eye Clinic Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Togano","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Niigata University Medical and Dental Hospital Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Fukuchi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology Niigata University Medical and Dental Hospital Niigata Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Alcon Japan Ltd. Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the JAC Study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.01.036"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00272-4"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(98)00223-2"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.936850"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S79843"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2013.867510"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-013-0284-2"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.121.1.48"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0b013e31818fb434"},{"key":"e_1_2_5_11_1","first-page":"623","article-title":"A patient preference comparison of Azarga (brinzolamide\/timolol fixed combination) vs Cosopt (dorzolamide\/timolol fixed combination) in patients with open\u2010angle glaucoma or ocular hypertension","volume":"2","author":"Mundorf TK","year":"2008","journal-title":"Clin Ophthalmol"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.03.026"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-012-0188-6"},{"key":"e_1_2_5_14_1","volume-title":"SAS\/STAT\u00ae 9.3 user's guide","author":"SAS Institute Inc.","year":"2011"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2013.0102"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S79680"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.05.033"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(00)00538-9"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0030"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3192"}],"container-title":["Acta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Faos.13401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/aos.13401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T20:48:21Z","timestamp":1695415701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/aos.13401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1111\/aos.13401"],"URL":"https:\/\/doi.org\/10.1111\/aos.13401","archive":["Portico"],"relation":{},"ISSN":["1755-375X","1755-3768"],"issn-type":[{"value":"1755-375X","type":"print"},{"value":"1755-3768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]},"assertion":[{"value":"2016-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-04-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}